Course Description
Symptoms of psychosis, including visual hallucinations and delusions, occur in up to 90% of patients with Parkinson’s Disease (PD), Parkinson’s Disease dementia (PDD), and dementia with Lewy bodies (DLB). The theme across these disorders includes the presence of alpha-synuclein pathology, and the pathophysiologic impact on converging brain networks. Identifying and managing these symptoms of psychosis represent a considerable challenge. Therapeutic limitations arise from the paucity of efficacious agents, deterioration in motor function due to dopamine receptor antagonism from conventional antipsychotics, interaction of sleep dysfunction and psychosis presentation, among other factors. As the management of psychosis can be complicated, many of these patients may seek specialized neuropsychiatric care; thus, psychiatric and neurologic pharmacists should be familiar with treatment strategies and pharmacotherapy utilized based on patient diagnosis.
Learning Objectives
- Describe clinical presentation of Parkinson’s Disease (PD), PD dementia (PDD), and dementia with Lewy bodies (DLB).
- Discuss prevalence and qualitative information related to psychosis in PD, dementia with Lewy bodies, and other atypical parkinsonian syndromes.
- Identify treatment strategies to manage psychotic symptoms in relationship to safety, efficacy, and currently available evidence.
- Outline information related to pimavanserin and its suggested indication for management of psychosis in dementia-related psychosis.
Target Audience
If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.
Faculty
View biographical information
Daniel O. Claassen, MD
Professor of Neurology
Vanderbilt University Medical Center
Nashville, TN
Dr. Claassen is a board-certified Neurologist, with subspecialty training in behavioral neurology and movement disorders, who specializes in the diagnosis and treatment of neurodegenerative disorders characterized by disruptions to cognition, behavior, and movement. The theme of his work is to understand the biologic basis of how humans regulate of behavior, and the cognitive processes intrinsic to this nature. His research efforts are focused in patients that suffer from neurodegenerative conditions, and current studies assess therapeutic outcomes in various neurodegenerative disorders, such as Parkinson, Huntington, and Alzheimer disease. He leads an active basic research lab which investigates the neurobiological basis neurodegeneration through innovative cognitive neuroscience, neuroimaging tools and biomarker discovery using patient biofluids. His expertise is in neuroimaging, neuropsychology methods, and clinical trials that assess therapeutic efficacy. Current research funding is from the National Institutes of Health, Department of Defense, Michael J Fox Foundation, Griffin Family Foundation, and several industry-academic partnerships.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
Activity Date: 04/26/2022
ACPE Contact Hours: 1
ACPE Number: 0284-0000-22-050-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View planning committee disclosures
2022 Program Committee
|
Elayne D. Ansara, PharmD, BCPP, BCPS Clinical Pharmacy Specialist Veteran Health Indiana Indianapolis, IN No Relevant Financial Relationships to Disclose |
 Jolene R. Bostwick, PharmD, BCPP, BCPSProgram Administrative Chair Assistant Dean for Co-Curriculum and Professional Development & Clinical Professor University of Michigan College of Pharmacy Ann Arbor, MI No Relevant Financial Relationships to Disclose |
|
Bridget Bradley, PharmD, BCPP |
|
|
|
Chelsea N. Carr, PharmD, BCPP Advanced Practice Pharmacist - Psychiatry University of Maryland School of Pharmacy Catonsville, MD No Relevant Financial Relationships to Disclose |
|
Dana Chiulli, PharmD, BCPP Clinical Pharmacist - Mental Health VISN 06 Mental Health Clinical Resource Hub Savannah, GA No Relevant Financial Relationships to Disclose |
|
Jordan Cooler, PharmD, BCPP Clinical Assistant Professor University of South Carolina College of Pharmacy Columbia, SC No Relevant Financial Relationships to Disclose |
|
Bennett J. Doughty, PharmD, BCPP, BCPS |
|
Amber R. Douglass, PharmD, BCPS, BCPP Clinical Pharmacy Specialist - Mental Health VISN 1 Clinical Resource Hub - VA Connecticut Healthcare System West Haven, CT No Relevant Financial Relationships to Disclose |
Megan J. Ehret, PharmD, BCPP, MS |
|
Kristen N. Gardner, PharmD, BCPP |
|
Michelle L. Geier, PharmD, BCPP Psychiatric Clinical Pharmacist Supervisor San Francisco Department of Public Health San Francisco, CA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Weitzman Institute Project ECHO Faculty |
|
Nicole Hahn, PharmD, BCACP Clinical Pharmacy Specialist - Neurology Kaiser Permanente Denver, CO No Relevant Financial Relationships to Disclose |
|
Kayla D. Johnson, PharmD, BCPP, BCPS Vanderbilt University Medical Center Thompsons Station, TN No Relevant Financial Relationships to Disclose |
|
Erin D. Knox, PharmD, BCPP Director of Experiential Education UCI School of Pharmacy & Pharmaceutical Sciences Irvine, CA Non-Financial Interests: Santa Ana Community College, Pharmacy Technology Program, Advisory Committee |
|
Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP Dean and Professor University of Montana, Skaggs School of Pharmacy Missoula, MT External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Editorial Board member: Continuum: Lifelong Learning in Neuroilogy, consultant for Lexicomp as a clinical specialist in neurology and psychiatry |
|
Melissa Mitchell, PharmD, BCGP, BCPP, BCPS Senior Clinical Pharmacist RUHS MC Moreno Valley , CA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Neurocrine Speakers Bureau - Ingrezza, Janssen Speakers Bureau - Spravato, Otsuka - PsychU.org Speaker |
|
Thea R. Moore, PharmD, BCPP Associate Professor University of South Florida Tampa, FL No Relevant Financial Relationships to Disclose |
|
Lindsey Peters, PharmD, BCPS Associate Professor of Pharmacy Practice Ohio Northern University Ada, OH No Relevant Financial Relationships to Disclose |
|
Kristina Reinstatler, PharmD, BCPP, MBA Clinical Pharmacy Specialist UC Health University of Cincinnati Medical Center Cincinnati, OH Educational Grants, Research Grants or Contracts: HEALing Communities NIH grant- pharmacy lead Athens Cty, Ohio |
|
Michael D. Shuman, PharmD, BCPP Staff Pharmacist Central State Hospital Lousiville, KY No Relevant Financial Relationships to Disclose |
|
Taylor A. Thomas, PharmD, BCPP Clinical Pharmacy Specialist- Mental Health VA Northern Indiana Health Care System Fort Wayne, IN No Relevant Financial Relationships to Disclose |
|
Nina Vadiei, PharmD, BCPP Assistant Professor University of Arizona Colleges of Pharmacy and Medicine Tucson, AZ No Relevant Financial Relationships to Disclose |
Austin R. Campbell, PharmD, BCPPAll relevant relationships have been mitigated.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Melatonin, Anticholinesterase inhibitors, Quetiapine
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.